Search

Your search keyword '"Clegg, Daniel O"' showing total 265 results
Start Over Author "Clegg, Daniel O"
265 results on '"Clegg, Daniel O"'

3. New Population‐Based Reference Values for Spinal Mobility Measures Based on the 2009–2010 National Health and Nutrition Examination Survey

Author

Assassi, Shervin, Weisman, Michael H, Lee, MinJae, Savage, Laurie, Diekman, Laura, Graham, Tiffany A, Rahbar, Mohammad H, Schall, Joan I, Gensler, Lianne S, Deodhar, Atul A, Clegg, Daniel O, Colbert, Robert A, and Reveille, John D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition, Obesity, Adult, Aged, Body Mass Index, Body Weight, Female, Humans, Male, Middle Aged, Nutrition Surveys, Range of Motion, Articular, Reference Values, Spine, Young Adult, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo report population-based percentile reference values for selected spinal mobility measures in a nationally representative sample of 5,001 US adults ages 20-69 years who were examined in the 2009-2010 US National Health and Nutrition Examination Survey (NHANES).MethodsOcciput-to-wall distance (OWD), thoracic expansion (TE), and anterior lumbar flexion (ALF; by modified Schober test) were measured by trained examiners in a standardized manner. TE was measured at the xiphisternal level, while the lower reference point for ALF was a line marked at the level of the superior margin of the lateral iliac crests. We report reference values based on the 95th percentile for the OWD and the 5th percentile for TE and ALF, as well as other summary statistics for these measures, in the study population.ResultsAn OWD of >0 was present in 3.8% of the participants, while 8.8% of them had out-of-range values for TE based on the commonly used threshold of 2.5 cm. The 95th percentile of the OWD measurement was 0, while the 5th percentile for TE and ALF were 1.9 cm and 2 cm, respectively. The spinal measures were significantly associated with sex, age, ethnicity, height, and body mass index (BMI). Exclusion of individuals with severe obesity (BMI >35 kg/m(2) ) changed the proposed reference values for TE and ALF to 2.2 cm and 1.9 cm, respectively.ConclusionWe verified a reference value of 0 for the OWD in the general population. Using the reported population-based percentile values, new reference values for TE and ALF can be derived.

Published
2014

12. Effect of Pulsed Low-Intensity Ultrasonography on Symptom Relief and Tibiofemoral Articular Cartilage Thickness Among Veterans Affairs Enrollees With Knee Osteoarthritis

Author

Sawitzke, Allen D., primary, Jackson, Christopher G., additional, Carlson, Kimberly, additional, Bizien, Marcel D., additional, Leiner, Mathew, additional, Reda, Domenic J., additional, Sindowski, Tom, additional, Hanrahan, Christopher, additional, Spencer, Richard G., additional, Kwoh, C. Kent, additional, Lee, Susan J., additional, Hose, Kalli, additional, Robin, Lisa, additional, Cain, Donna W., additional, Taylor, Meredith D., additional, Bangerter, Neal, additional, Finco, Martha, additional, and Clegg, Daniel O., additional

Published
2022
Full Text
View/download PDF

14. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis

Author

Bekele, Delamo I., primary, Cheng, Elizabeth, additional, Reimold, Andreas, additional, Geier, Christian, additional, Ganuthula, Kavya, additional, Walsh, Jessica A., additional, Clegg, Daniel O., additional, Dubreuil, Maureen, additional, Kaushik, Prashant, additional, Ng, Bernard, additional, Chang, Elizabeth, additional, Duong, Ryan, additional, Park, Jina, additional, and Kerr, Gail S., additional

Published
2021
Full Text
View/download PDF

16. The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administrationʼs Comments and Concerns

Author

Deodhar, Atul, Reveille, John D., van den Bosch, Filip, Braun, Jürgen, Burgos-Vargas, Ruben, Caplan, Liron, Clegg, Daniel O., Colbert, Robert A., Gensler, Lianne S., van der Heijde, Désirée, van der Horst-Bruinsma, Irene E., Inman, Robert D., Maksymowych, Walter P., Mease, Philip J., Raychaudhuri, Siba, Reimold, Andreas, Rudwaleit, Martin, Sieper, Joachim, Weisman, Michael H., and Landewé, Robert B. M.

Published
2014
Full Text
View/download PDF

19. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

Author

Clegg, Daniel O., Bingham, Clifton O., III, Schumacher, H. Ralph, Jr., Furst, Daniel E., Brandt, Kenneth D., O'Dell, James R., Harris, Crystal L., Klein, Marguerite A., Reda, Domenic J., Lane, Nancy E., Cush, John J., Moreland, Larry W., Weisman, Micheal H., Jackson, Christopher G., Molitor, Jerry A., Yocum, David E., Schnitzer, Thomas J., Oddis, Chester V., Wolfe, Frederick, Sawitzke, Allen D., Shi, Helen, Moskowitz, Roland W., Williams, H. James, Hooper, Michael M., and Bradley, John D.

Subjects
Osteoarthritis -- Drug therapy, Glucosamine -- Dosage and administration, Chondroitin -- Dosage and administration
Abstract

Glucosamine and chondroitin sulphate are used to treat osteoarthritis, and the multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthiritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. Exploratory analyzes suggest that the combination of glucosamine and chondroitin sulphate may be effective in the subgroup of patients with moderate-to-severe knee pain.

Published
2006

24. Contributors

Author

Alkassab, Firas, primary, Baeten, Dominique, additional, Braun, Juergen, additional, Chan, Antoni, additional, Clegg, Daniel O., additional, De Keyser, Filip, additional, Diamantis, Stephanie, additional, Elder, James T., additional, Espinoza, Luis R., additional, Fearon, Ursula, additional, FitzGerald, Oliver, additional, Frech, Tracy M., additional, Gladman, Dafna D., additional, Gudjonsson, Johann E., additional, Hamdulay, Shahir, additional, Helliwell, Philip S., additional, Inman, Robert D., additional, Kane, David John, additional, Kavanaugh, Arthur, additional, Keat, Andrew, additional, Kingsley, Gabrielle H., additional, Kruithof, Elli, additional, Lebwohl, Mark, additional, Leirisalo-Repo, Marjatta, additional, McGonagle, Dennis, additional, McHugh, Neil, additional, Mease, Philip, additional, Mielants, Herman, additional, Nash, Peter, additional, O'Shea, Finbar D., additional, Rahman, Proton, additional, Reveille, John D., additional, Ritchlin, Christopher T., additional, Ruderman, Eric, additional, Scott, David L., additional, Sieper, Joachim, additional, Tan, Ai Lyn, additional, Taylor, William J., additional, Toivanen, Auli, additional, Cruyssen, Bert Vander, additional, Veale, Douglas J., additional, Winchester, Robert, additional, and Wordsworth, Paul, additional

Published
2007
Full Text
View/download PDF

26. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT

Author

Sawitzke, Allen D, Shi, Helen, Finco, Martha F, Dunlop, Dorothy D, Harris, Crystal L, Singer, Nora G, Bradley, John D, Silver, David, Jackson, Christopher G, Lane, Nancy E, Oddis, Chester V, Wolfe, Fred, Lisse, Jeffrey, Furst, Daniel E, Bingham, Clifton O, Reda, Domenic J, Moskowitz, Roland W, Williams, H James, and Clegg, Daniel O

Published
2010
Full Text
View/download PDF

27. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

Author

Walsh, Jessica A., primary, Pei, Shaobo, additional, Penmetsa, Gopi K., additional, Sauer, Brian C., additional, Patil, Vikas, additional, Walker, Jodi H., additional, Clewell, Jerry, additional, Douglas, Kevin M., additional, Clegg, Daniel O., additional, Cannon, Grant W., additional, and Halwani, Ahmad, additional

Published
2019
Full Text
View/download PDF

28. Reply

Author

Sawitzke, Allen D., Shi, Helen, Finco, Martha F., Dunlop, Dorothy D., Harris, Crystal L., Reda, Domenic J., Williams, James H., and Clegg, Daniel O.

Published
2009
Full Text
View/download PDF

29. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial

Author

Sawitzke, Allen D., Shi, Helen, Finco, Martha F., Dunlop, Dorothy D., Bingham, Clifton O., III, Harris, Crystal L., Singer, Nora G., Bradley, John D., Silver, David, Jackson, Christopher G., Lane, Nancy E., Oddis, Chester V., Wolfe, Fred, Lisse, Jeffrey, Furst, Daniel E., Reda, Domenic J., Moskowitz, Roland W., Williams, H. James, and Clegg, Daniel O.

Published
2008

32. Screening the Genome for Rheumatoid Arthritis Susceptibility Genes: A Replication Study and Combined Analysis of 512 Multicase Families

Author

Jawaheer, Damini, Seldin, Michael F., Amos, Christopher I., Chen, Wei V., Shigeta, Russell, Etzel, Carol, Damle, Aarti, Xiao, Xiangli, Chen, Dong, Lum, Raymond F., Monteiro, Joanita, Kern, Marlene, Criswell, Lindsey A., Albani, Salvatore, Nelson, Lee J., Clegg, Daniel O., Pope, Richard, Schroeder, Harry W., Jr., Bridges, Louis S., Jr., Pisetsky, David S., Ward, Ryk, Kastner, Daniel L., Wilder, Ronald L., Pincus, Theodore, Callahan, Leigh F., Flemming, Donald, Wener, Mark H., and Gregersen, Peter K.

Published
2003

41. Comparison of Sulfasalazine and Placebo in the Treatment of Reactive Arthritis (Reiter's Syndrome): A Department of Veterans Affairs Cooperative Study

Author

Clegg, Daniel O., Reda, Domenic J., Weisman, Michael H., Cush, John J., Vasey, Frank B., Schumacher, H. Ralph, Budiman-Mak, Elly, Balestra, Dominic J., Blackburn, Warren D., Cannon, Grant W., Inman, Robert D., Alepa, F. Paul, Mejias, Edwin, Cohen, Miriam R., Makkena, Rama, Mahowald, Maren L., Higashida, Jean, Silverman, Stuart L., Parhami, Nourollah, Buxbaum, Joel, Haakenson, Clair M., Ward, Richard H., Manaster, B. J., Anderson, Robert J., Ward, John R., and Henderson, William G.

Published
1996

42. Comparison of Sulfasalazine and Placebo in the Treatment of Psoriatic Arthritis: A Department of Veterans Affairs Cooperative Study

Author

Clegg, Daniel O., Reda, Domenic J., Mejias, Edwin, Cannon, Grant W., Weisman, Michael H., Taylor, Thomas, Budiman-Mak, Elly, Blackburn, Warren D., Vasey, Frank B., Mahowald, Maren L., Cush, John J., Schumacher, H. Ralph, Silverman, Stuart L., Alepa, F. Paul, Luggen, Michael E., Cohen, Miriam R., Makkena, Rama, Haakenson, Clair M., Ward, Richard H., Manaster, B. J., Anderson, Robert J., Ward, John R., and Henderson, William G.

Published
1996

43. Comparison of Sulfasalazine and Placebo in the Treatment of Ankylosing Spondylitis: A Department of Veterans Affairs Cooperative Study

Author

Clegg, Daniel O., Reda, Domenic J., Weisman, Michael H., Blackburn, Warren D., Cush, John J., Cannon, Grant W., Mahowald, Maren L., Schumacher, H. Ralph, Taylor, Thomas, Budiman-Mak, Elly, Cohen, Miriam R., Vasey, Frank B., Luggen, Michael E., Mejias, Edwin, Silverman, Stuart L., Makkena, Rama, Alepa, F. Paul, Buxbaum, Joel, Haakenson, Clair M., Ward, Richard H., Manaster, B. J., Anderson, Robert J., Ward, John R., and Henderson, William G.

Published
1996

44. HLA-DRB1 Genes and Disease Severity in Rheumatoid Arthritis

Author

Reveille, John D., Alarcon, Graciela S., Fowler, Sarah E., Pillemer, Stanley R., Neuner, Rosemarie, Clegg, Daniel O., Mikhail, Isis S., Trentham, David E., Leisen, James C. C., Bluhm, Gilbert, Cooper, Sheldon M., Duncan, Howard, Tuttleman, Marilyn, Heyse, Stephen P., Sharp, John T., and Tilley, Barbara

Published
1996

47. The Role of T Cell Receptor beta Chain Genes in Susceptibility to Rheumatoid Arthritis

Author

McDermott, Michael, Kastner, Daniel L., Holloman, John D., Schmidt-Wolf, Gabriele, Lundberg, Ante S., Sinha, Animesh A., Hsu, Christine, Cashin, Patrick, Molloy, Michael G., Mulcahy, Brian, O'Gara, Fergal, McConnell, Fiona I., Adams, Claire, Khan, Muhammad A., Wolfe, Frederick, Rubin, Laurence A., Clegg, Daniel O., Husebye, Dee, Amos, Christopher I., Ward, Ryk H., and McDevitt, Hugh O.

Published
1995

48. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA

Author

Walsh,Jessica A, Jones,Heather, Mallbris,Lotus, Callis Duffin,Kristina, Krueger,Gerald G, Clegg,Daniel O, Szumski,Annette, Walsh,Jessica A, Jones,Heather, Mallbris,Lotus, Callis Duffin,Kristina, Krueger,Gerald G, Clegg,Daniel O, and Szumski,Annette

Abstract

Jessica A Walsh,1 Heather Jones,2 Lotus Mallbris,2 Kristina Callis Duffin,3 Gerald G Krueger,3 Daniel O Clegg,1 Annette Szumski4 1Division of Rheumatology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; 2Inflammation and Immunology,Global Medical Affairs, Pfizer, Collegeville, PA, USA; 3Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA; 4Pfizer Business Unit (PBU) Syneos Health, Princeton, NJ, United States Background: The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments. Methods: The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland–Altman plots, and Kappa statistics. Results: Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87, and 0.90, respectively; all P<0.0001) as were intra-class correlations (0.76 [95% confidence interval 0.73–0.80], 0.80 [0.76–0.83], and 0.85 [0.82–0.87], respectively). The effect size was −1.53 for PASI and −0.94 for PGA × BSA (baseline to week 24). Scatterplots and Bland–Altman plots detected a trend across the range of measurement. Kappa statistics (at 12 and 24 weeks) between PASI50/75/90 and 50/75/90% improvement in PGA × BSA showed good agreement (0.58–0.69 at week 12 and 0.63–0.67, respectively; all P&

Published
2018

50. Outcome and prognostic indicators in early scleroderma (systemic sclerosis): early undifferentiated connective tissue disease, part 3

Author

Bulpitt, Ken J., Clements, Philip J., Lachenbruch, Peter A., Paulus, Harold E., Peter, James B., Agopian, Mel S., Singer, Joyce Z., Steen, Virginia D., Clegg, Daniel O., Ziminski, Carol M., Alarcon, Graciela S., Luggen, Michael E., Polisson, Richard P., Willkens, Robert F., Reading, James C., Williams, H. James, and Ward, John R.

Subjects
Systemic scleroderma -- Risk factors, Scleroderma (Disease) -- Health aspects, Health
Abstract

* Objective: To characterize the course of early scleroderma and to delineate prognostic factors present within 1 year of disease onset that might identify patients at high risk. * Design: Inception cohort study. * Setting. Ten university-based rheumatology clinics participating in the Cooperative Systematic Studies of Rheumatic Diseases Program. * Patients: Forty-eight patients who had had scleroderma for less than 1 year. * Measurements: Fifteen patients with early scleroderma who died were compared with those still living during the initial study period (1982 to 1992). Kaplan-Meier survival estimation and Cox proportional hazards analysis were used to analyze baseline variables for their ability to predict survival duration. * Results: Eight of 15 deaths were due to cardiac or pulmonary system failure. The estimated 5-year survival rate was 68%. Baseline factors that were the most predictive of a poor outcome included the presence of abnormal cardiopulmonary signs and abnormal urine sediment (pyuria, hematuria). * Conclusion: Evidence of early cardiopulmonary disease, renal disease, inflammation, or immune activation may identify a subset of patients with scleroderma who will experience rapidly progressive disease and early death., Heart and kidney involvement among patients with scleroderma appear to be associated with rapid progression of the disease and diminished survival. Scleroderma is characterized by hardening and thickening of the skin and may involve degeneration of various body organs. Some patients live with scleroderma for 10 to 20 years while others develop a rapidly progressive form resulting in early organ failure and death. Of 47 patients with early scleroderma, 15 died within five years. Five of them died within one year of developing symptoms. Initially, 80% of the patients who eventually died had at least one heart abnormality compared with 41% of the survivors. Initial heart rate averaged 93 beats per minute among those who eventually died compared with 79 beats per minute among survivors. There was no difference in skin involvement between the two groups. Kidney abnormalities occurred in 40% of those who died and in 16% of the survivors. Ongoing inflammation and immune system activation were also more common among those who died.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results